Esperion Therapeutics (ESPR) Free Cash Flow (2012 - 2026)
Esperion Therapeutics (ESPR) posted Free Cash Flow of -$27.9 million for Q1 2026, down 161.95% on a QoQ basis from $45.1 million in Q4 2025, and down 23.35% year-over-year from -$36.4 million in Q1 2025.
Esperion Therapeutics (ESPR) Free Cash Flow (2012 - 2026) Analysis & Trends
Esperion Therapeutics' Free Cash Flow history runs 15 years deep, the most recent figure standing at -$27.9 million for Q1 2026.
- Quarterly Free Cash Flow fell 23.35% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.6 million (up 81.5% YoY) and the FY2025 annual result came in at -$13.3 million, up 44.59% from the prior year.
- Free Cash Flow was -$27.9 million for Q1 2026 at Esperion Therapeutics, down from $45.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $53.8 million in Q1 2024 and bottomed at -$54.4 million in Q1 2023.
- A 5-year average of -$22.1 million and a median of -$31.4 million in 2025 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 228.9% in 2025, while the deepest fall reached 330.5% in 2025.
- Esperion Therapeutics' Free Cash Flow stood at -$42.5 million in 2022, then gained by 12.75% to -$37.1 million in 2023, then rose by 5.68% to -$35.0 million in 2024, then jumped by 228.9% to $45.1 million in 2025, then sank by 161.95% to -$27.9 million in 2026.
- Business Quant data shows ESPR's Free Cash Flow at -$27.9 million in Q1 2026, $45.1 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn | -27.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.91 Mn |
| Mar 31, 2026 | -27.91 Mn |
| Dec 31, 2025 | 45.05 Mn |
| Dec 31, 2025 | 45.05 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Sep 30, 2025 | -4.29 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Mar 31, 2025 | -22.63 Mn |
| Mar 31, 2025 | -22.63 Mn |
| Dec 31, 2024 | -34.95 Mn |
| Dec 31, 2024 | -34.95 Mn |
| Sep 30, 2024 | -35.48 Mn |
| Sep 30, 2024 | -35.48 Mn |
| Jun 30, 2024 | -7.30 Mn |
| Jun 30, 2024 | -7.30 Mn |
| Mar 31, 2024 | 53.76 Mn |
| Mar 31, 2024 | 53.76 Mn |
| Dec 31, 2023 | -37.06 Mn |
| Dec 31, 2023 | -37.06 Mn |